Additionally, studies have pointed out that ornithine decarboxylase (ODC) is a potential target for esophageal squamous cell carcinoma treatment, with its inhibitor, difluoromethylornithine (DFMO), undergoing clinical trials for related cancers (He et al., 2017), and has been used in clinical trials for the treatment of pediatric neuroblastoma (Lozier et al., 2015). The gene discussed is ODC1; the disease is esophageal squamous cell carcinoma.